Newbury Pharmaceuticals management has purchased shares in the company

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Newbury Pharmaceuticals management has purchased shares in the company

Since last week management in Newbury has purchased a total of 77 000 shares in the company, Karl Karlsson Chairman 50 000 shares, Andrea Karnitschky Head of Business Development 20 000 shares and Lars Minor CEO 7 000 shares.

The transactions have been reported to the Financial Supervisory Authority in accordance with current regulations and the information appears in the Financial Supervisory Authority's register for insider trading

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Datum	2022-09-07, kl 13:15
Källa	MFN

Bifogade filer

Newbury Pharmaceuticals management has purchased shares in the company

LOGGA IN

Newbury Pharmaceuticals

Affiliate

Newbury Pharmaceuticals management has purchased shares in the company